Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

Today, the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, issued a positive opinion for a ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

Wegovy may significantly reduce hospital admissions for any cause and overall length of stay, according to a new analysis of data from Novo Nordisk's phase 3 SELECT trial. Compared to patients taking ...

Wegovy and Zepbound, two popular weight loss GLP-1 medications, would remain cost-effective at a higher price, according to an Oct. 29 revised report from the Institute for Clinical and Economic ...

NEW YORK, May 21 (Reuters) - Cigna (CI.N), opens new tab will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy ...

When it comes to losing weight, there’s a sea of options out there, and it can get pretty confusing trying to figure out what might work best for you. I know the feeling; I’ve been there myself, ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by more ...